Lung cancer growth inhibition and autophagy activation by tetrazole via ERK1/2 up-regulation and mTOR/p70S6K signaling down-regulation

Liangjian Zheng1,2, Jun Zhang1,2, Jia Fan1,2, Yuxin He1,2, Tingting Zhan1,2, Liwen Rong1,2, Mengzhen Yuan1,2 and Hongyan Zhang1,2

1Department of Oncology, The Third People’s Hospital of Chengdu, Chengdu, Sichuan, 610031, China; 2Department of Oncology, The Affiliated Hospital of Southwest Jiaotong University, Chengdu, Sichuan, 610031, China; 3Department of Laboratory Medicine, Eastern Hospital, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Chengdu, Sichuan, 610101, China

INTRODUCTION

Lung cancer, a most common clinically diagnosed malignancy grows rapidly and undergoes metastasis/diffusion to distant organs at a fast rate. In the present study, gravaclidoneol tetrazole (tetrazole) was synthesized and investigated for lung cancer growth inhibition potential in vitro. MTT assay and flow cytometry using propidium iodide were used to determine viability changes and DNA content distribution. Protein expression and apoptotic changes were detected by western blotting and Annexin-V/PI assays. Treatment with 12 μM tetrazole suppressed viabilities to 23% and 20% in A549 and NCI-H1819 cells, respectively. In tetrazole exposed cells, G1-phase cell count increased significantly compared to the control. Tetrazole-treatment of A549 and NCI-H1819 cells caused a prominent raise in LC3-II and p-ERK1/2 expression at 72 h. The SQSTM1/p62 level, p-mTOR and p-p70S6K expression was lowered significantly in A549 and NCI-H1819 cells on exposure to tetrazole. Exposure to U1026 alleviated tetrazole mediated LC3II/I ratio increase in A549 and NCI-H1819 cells significantly (P<0.02) compared to tetrazole treated cells. Treatment with tetrazole and 3-MA in combination led a significant (P<0.02) elevation in A549 and NCI-H1819 cell apoptotic count relative to tetrazole (12 μM) alone treated cells. Moreover, tetrazole and 3-MA combination increased cleavage of caspase-3 to a greater extent compared to tetrazole. In summary, tetrazole manifested anti-proliferative effect on lung cancer cells via autophagy over-activation and arrest of cell cycle. It deactivated ERK1/2 signalling and promoted mTOR signaling in A549 and NCI-H1819 cells to regulate cancer proliferation. Thus, tetrazole needs to be studied further as an anti-proliferative agent for treatment of lung cancer.

Keywords: tetrazoles, autophagy, metastasis, anti-proliferative, apoptosis

Received: 09 July, 2021; revised: 08 August, 2021; accepted: 30 August, 2021; available on-line: 28 February, 2022

Abbreviations: TGF-β, Transforming growth factor-β (TGF-β); DMEM, Dulbecco’s modified Eagle’s medium; MTT, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; BrdU, bromodeoxyuridine; PDGFRs, Platelet-derived growth factor receptors

Tetrazole fragment constitutes a promising pharmacophore and is being synthesized in many compounds to improve bioactivity in drug development program (Favata et al., 1998). Flexibility combined with stability on binding to various targets is the main factor which led to advances in tetrazole chemistry (Fukazawa et al., 2002). Another characteristic property that attracts towards tetrazoles as pharmacophores is their ability to act
as carboxylic functionality mimicking agents. Because of this property tetrzoles showed effective anti-inflammatory potential (Sharma et al., 2018) and act as analgesics and antiulcer agents (Tang et al., 2017). Gravacridondiol is isolated from Ruta graveolens L. that is a perennial herb, originally native of the Mediterranean region (Tanida, 2011). Formulations of R. graveolens have been used to inhibit progression or to completely repress the glioma growth in human brains without causing toxicity (Klionsky et al., 2012). In the present study gravacridondiol tetrzole (tetrazole) was synthesized and investigated for lung cancer growth inhibition potential in vitro. Additionally, the mechanism associated with tetrazole mediated cell death was also explored.

MATERIALS AND METHODS

Cell culture

Beas-2B normal epithelial lung cells, A549 and NCI-H1819 lung cancer cell lines were procured from ATCC (Manassas, VA, USA) and grown in DMEM (HyClone, Logan, UT) mixed with FBS (10%). Medium was also mixed with penicillin (100 U/mL) and streptomycin (100 mg/mL). The cells were incubated overnight at 37°C in an incubator under 5% CO₂ and 95% air atmosphere.

Synthesis of gravacridondiol tetrzole (tetrazole)

R. graveolens plant material was obtained from the China-Ladakh boarder and identified by Prof. Zhang Li. Roots of the plant were dried under shade, chopped, and then finely powdered in grinders to collect the powder. The powdered plant material was extracted in ethyl acetate solvent for 48 h, the solvent was decanted and concentrated in rotary vacuum evaporator to obtain the extract. The extract was mixed with silica gel to prepare slurry, which was loaded onto a silica gel column to isolate the gravacridondiol compound.

The solution of gravacridondiol in aqueous alcohol was treated with 1,3-diido-5,5-dimethylhydantoin (2 equivalent; DIH) in the dark at 70°C for 12 h. The crude nitride compound (2; Scheme 1) was purified by column chromatography, dried, and then weighed. The nitride (2; Scheme 1) obtained was dissolved in DMF and then reacted with sodium azide (2 equivalent) and iodine (6 mol%) for 24 h at 60°C to obtain the desired tetrazole (3; Scheme 1). Impure tetrazole (3; Scheme 1) was loaded onto a column and purified using ethyl acetate/petroleum ether (50:50) solvent system. Tetrazole was characterized using spectral techniques like 1H NMR, HRMS and IR spectroscopy.

Viability assay

The cellular density in 96-well plates was adjusted at 2×10^4 cells/well and grown for overnight in an incubator at 37°C. Tetrzole at 1.5, 3, 6 and 12 μM was mixed with DMEM and cell incubation was performed for 72 h with it. Then, medium from the wells was replaced by fresh medium free from tetrzole. Afterwards, MTT solution (0.5 mg/ml) was poured into each well and incubation of cells was carried out for 4 more hours under the same conditions. Discarding of medium from the wells was followed by an addition of 100 μl DMSO solubilization solution. Gentle shaking of plates to uniformly mix the colour was followed by optical density measurements, in triplicates, at 570 nm using the microplate reader (Wellscan MK3, Labsystems, Finland).

Cell cycle analysis

The cells were distributed at 2×10^4 cells/well density in 6-well plates and cultured for overnight at 37°C. Cellular distribution in different phases was detected following propidium iodide (Sigma-Aldrich) staining of the DNA content. Briefly, trypsinization and then overnight fixing in 70% ethyl alcohol were followed by PBS-washing of the cells two times. Afterwards, centrifugation was performed at 235×g and the separated cells were treated for 15 min with RNase (50 μl) prior to PI (50 μg/ml) staining for 2 h. The FACSAria II instrument for flow cytometry and CellQuest7.6.2 software (BD Biosciences, CA, USA) was employed for the determination of cell fraction in various cell cycle phases.

Western blotting

The cells were distributed at 2×10^4 cells/well density in 6-well plates and incubated with tetrzole at 6 and 12 μM for 72 h. Exposure to tetrzole was followed by cell washing two times with cold-PBS and treatment with lysis buffer consisting of NP-40 (1%), sodium phosphate (5 mM), sodium chloride (150), Tris-HCl (pH 7.5; 20 mM), Na₃VO₄ (5 mM), PMSF (1 mM) and leupeptin (10 μg/ml). Lysate formed after 30 min was centrifuged for 20 min at 15,000×g to collect the supernatants in which protein content was estimated by BCA kits. Samples were loaded in equal amounts (20 μg) to resolve bands on 12% SDS-PAGE followed by transfer onto the PVDF-membranes. Membrane incubation was made at 4°C with primary antibodies overnight, followed by PBS/Tween 20 washing for 1 h. Afterwards, incubation was carried out with the secondary antibodies conjugated to the goat anti-rabbit IgG for 2 h at room temperature. Band visualization was made using SignalFire™ ECL Reagent (Cell Signaling Technology, Inc.) and quantification by Image J version 2.0 software (Bio-Rad Laboratories Inc, USA). Antibodies used were against: p-ERK1/2 (dilution 1:2000), p-mTOR (dilution 1:1200), LC3 (dilution 1:1200), sequestosome-1 (SQSTM1/p62; dilution 1:2000), ERK1/2 mTOR (dilution 1:2000) and β-actin (dilution 1:1200; all from Cell Signaling Technology, Inc, USA). Antibodies used were against: p-ERK1/2 (dilution 1:2000), LC3 (dilution 1:1200), sequestosome-1 (SQSTM1/p62; dilution 1:2000), ERK1/2 mTOR (dilution 1:1200), p-mTOR (dilution 1:1200), p-p70S6K (dilution 1:2000) and β-actin (dilution 1:1200; all from Cell Signaling Technology, Inc., Danvers, MA, USA).

Apoptosis assays

Cells were seeded at 2×10^4 cells/well density in 6-well plates and incubated with tetrzole at 12 μM for 72 h. Cells exposed to tetrzole were stained as per instructions of the supplier with Annexin V/PI (BD Biosciences, NJ, USA) for apoptosis detection. Incubation of A549 and NCI-H1819 cells with Annexin-V/PI was performed in the dark for 20 min. Then, apoptosis was observed in cells by a flow cytometer (BD Biosciences, NJ, USA) and data obtained was analysed using WinMDI version 2.5.

Statistical analysis

Data analysis was made using SPSS version-17.0 software (SPSS, Inc, Chicago, IL, USA). All the data obtained in present study are expressed as the mean ± standard deviations of triplicate measurements. One-way analysis of variance (ANOVA) and Tukey’s post-hoc test was used for statistical analysis of the data. At P<0.05 differences denoted statistically significant differences.
RESULTS

Tetrazole suppresses A549 and NCI-H1819 cell viability

Tetrazole was synthesised in two steps from gravacridondiol using 1,3-diiodo-5,5-dimethylhydantoin (DIH) as reagent (Scheme 1). Viability changes by tetrazole at 0.75, 1.5, 3, 6 and 12 μM in A549 and NCI-H1819 cells were measured using MTT assay (Fig. 1). In tetrazole-treated cells a significant ($P<0.05$) suppression in viability was measured in dose-based manner with an increase in the tetrazole concentration. Tetrazole treatment of A549 and NCI-H1819 cells suppressed viabilities to 89% and 86%, respectively at 0.75 μM concentration. Treatment with 12 μM tetrazole suppressed viabilities to 23% and 20%, respectively in A549 and NCI-H1819 cells. Tetrazole treatment did not affect the viability of Beas-2B normal epithelial lung cells (not shown).

Tetrazole leads to A549 and NCI-H1819 cell cycle arrest in G1-phase

Tetrazole exposure at 6 and 12 μM for 72 h was followed by flow cytometric detection of A549 and NCI-H1819 cells for cell cycle changes (Fig. 2A, B). In 12

Figure 1. Effect of tetrazole on A549 and NCI-H1819 cell viability. Exposure to tetrazole at 0.75, 1.5, 3, 6 and 12 μM was followed by determination of viability changes in (A) A549 and (B) NCI-H1819 cells at 12, 24, 36, 48 and 72 h. *$P<0.05$, **$P<0.02$ vs. without tetrazole.

Figure 2. Effect of tetrazole on A549 and NCI-H1819 cell cycle. Exposure to tetrazole at 6 and 12 μM was followed by flow cytometry for detection of DNA content in (A, C) A549 and (B, D) NCI-H1819 cells at 72 h. *$P<0.05$, **$P<0.02$ vs. without tetrazole.

Tetrazole promotes LC3-II and lowers SQSTM1/p62 in A549 and NCI-H1819 cells

In tetrazole-treated A549 and NCI-H1819 cells a prominent raise in LC3-II expression was observed at 72 h relative to control (Fig. 3). Tetrazole induced LC3-II expression increase was higher in 12 μM exposed
A549 and NCI-H1819 cells compared to cells exposed to 6 μM. The level of SQSTM1/p62 expression showed a marked lowering in A549 and NCI-H1819 cells on exposure to tetrazole. Lowering of SQSTM1/p62 expression by tetrazole treatment was more prominent in 12 μM treated A549 and NCI-H1819 cells relative to 6 μM exposed cells.

Tetrazole regulates ERK1/2 and mTOR phosphorylation in A549 and NCI-H1819 cells

The p-ERK1/2 level showed a prominent enhancement in A549 and NCI-H1819 cells on exposure to tetrazole at 6 and 12 μM (Fig. 4A). In 12 μM tetrazole treated cells, p-ERK1/2 expression was enhanced to maximum level compared to 6 μM treated A549 and NCI-H1819 cells. Exposure of A549 and NCI-H1819 cells to 6 and 12 μM tetrazole significantly lowered p-mTOR expression at 72 h relative to the control (Fig. 4B). Treatment with tetrazole caused significant (*P<0.02) inhibition of p-p70S6K expression in A549 and NCI-H1819 cells at 6 and 12 μM doses.

Tetrazole mediated LC3II/I increase in A549 and NCI-H1819 cells is reversed by U0126

Tetrazole treatment at 12 μM significantly (*P<0.05) raised LC3II/I ratio in A549 and NCI-H1819 cells relative to control (Fig. 5). However, exposure to U0126 alleviated tetrazole mediated LC3II/I ratio increase in A549 and NCI-H1819 cells significantly (*P<0.02) compared to tetrazole treated cells.

Tetrazole promotes A549 and NCI-H1819 cell apoptosis

Significant (*P<0.05) rise in apoptotic cell count was observed in A549 and NCI-H1819 cells on treatment with tetrazole at 12 μM (Fig. 6). Exposure to 3-MA could not increase A549 and NCI-H1819 cell apoptotic percentage when compared to the control cells. Treatment with tetrazole (12 μM) and 3-MA in combination led a significant (*P<0.02) elevation in A549 and NCI-H1819 cell apoptotic count relative to tetrazole (12 μM) alone treated cells.

Tetrazole mediated A549 and NCI-H1819 cell apoptosis is elevated by 3-MA

In A549 and NCI-H1819 cells tetrazole treatment promoted caspase-3 cleavage markedly at 12 μM doses relative to control cells (Fig. 7). Exposure to 3-MA could not increase caspase-3 cleavage in A549 and NCI-H1819 cells. However, when A549 and NCI-H1819 cells were treated with tetrazole and 3-MA combination cleaved caspase-3 level showed marked up-regulation relative to tetrazole-treated cells.

DISCUSSION

Chemotherapeutic strategy for cancer has advanced into a novel era wherein molecular pathways are targeted using highly selective drugs that are free from conventional cytotoxicity (Bursch, 2001). Invented tetrazole derivatives were found to be highly active and yielded promising results as anti-cancer agents (Mihaylova et al., 2011). Compounds containing tetrazole rings have been demonstrated to exhibit diversity of biological activities (Pyö et al., 2012). The present study found that tetrazole repressed A549 and NCI-H1819 cancer cells viability depending upon the concentration added. Tetrazole exposed A549 and NCI-H1819 cells were examined by flow cytometry for possible changes in cell cycle progression. It was found that tetrazole exposure induced an arrest of cell cycle in A549 and NCI-H1819 cells in G1-phase. Tetrazole (12 μM) exposure raised A549 and NCI-H1819 cell population from 43% to more than 70% in the G1-phase. Consequently, significant (*P<0.05) lowering of cell population in S and
G2/M phases was found in tetrazole exposed A549 and NCI-H1819 cells. Autophagy is actually a process of homeostasis associated with delivery of various intracellular constituents to be degraded into the lysosomes. Besides several environmental stresses, chemotherapeutics also activate autophagy in tumor cells in different organs (Schmidt-Kittler et al., 2010). Over-activated autophagy acts as another process to eliminate cells in programmed but nonapoptotic way (Kharas et al., 2010). A prominent marker indicating autophagy activation is the expression of LC-3 formed from LC3-I (Dancey et al., 2012). There is also a reduction in p62 level because of its degradation along with other autophagosomal contents during autophagy activation (Cagnol et al., 2010). In the present study tetrazole-treatment of A549 and NCI-H1819 cells led to a prominent raise in LC3-II expression relative to control cells. Moreover, tetrazole mediated LC3-II expression increase was higher in 12 μM exposed A549 and NCI-H1819 cells compared to the cells exposed to 6 μM. Additionally, SQSTM1/p62 level showed a remarkable lowering in A549 and NCI-H1819 cells on exposure to tetrazole. This indicates that tetrazole treatment over-activates autophagy in A549 and NCI-H1819 cells, leading to growth inhibition.

Autophagy induction associated with nutrient starvation or other stress factors is regulated mainly by two pathways such as mTOR and ERK1/2 (Popova et al., 2017). Elevation in p-ERK expression in bladder (J82 & 5637 cells) and adrenocortical carcinoma cells has been demonstrated to over-activate autophagy and inhibit tumor growth (Bachar et al., 2004). It is reported that mTORC1 avoids autophagy via deactivation of proteins and induction of mTOR and p70S6K phosphorylation (Natrajan et al., 2010). In the present study p-ERK1/2 level showed a prominent enhancement in A549 and NCI-H1819 cells on exposure to tetrazole at 6 and 12 μM. Exposure of A549 and NCI-H1819 cells to 6 and 12 μM tetrazole significantly lowered p-mTOR expression at 72 h relative to the control. Treatment with tetrazole caused significant (P<0.02) inhibition of p-p70S6K expression in A549 and NCI-H1819 cells at 6 and 12 μM doses.

Inhibition of MEK1/MEK2 belonging to MAPK/ERK kinases is achieved in a highly selective manner using U0126 (Hallinan et al., 2002). It is established that U0126 effectively blocks ERK pathway (Meepagala et al., 2005) and because of this A549 and NCI-H1819 cells were exposed to U0126 to confirm tetrazole mediated ERK1/2 activation. In the present study tetrazole treatment significantly (P<0.05) raised LC3II/I ratio in A549 and NCI-H1819 cells relative to control. However, exposure to U0126 alleviated tetrazole mediated LC3II/I ratio increase in A549 and NCI-H1819 cells significantly (P<0.02) compared to tetrazole treated cells.

Autophagy mediated cell death has been confirmed previously in carcinoma cells during antineoplastic studies (Pathak et al., 2003). The present study used 3-MA to block tetrazole mediated autophagy induction and investigate any increase in cell apoptosis. A significant

![Figure 6. Effect of 3-MA and tetrazole on apoptosis.](image)

A549 and NCI-H1819 cells were treated with tetrazole at 12 μM and then exposed to 3-MA at 5 μM doses for 72 h. Apoptotic death in A549 and NCI-H1819 cells was detected by Flow cytometry. *P<0.05, **P<0.02 vs. without tetrazole.

![Figure 7. Effect of 3-MA and tetrazole on caspase-3 activation.](image)

A549 and NCI-H1819 cells were treated with tetrazole at 12 μM and then exposed to 3-MA at 5 μM doses for 72 h. Activated caspase-3 was examined in (A) A549 and (B) NCI-H1819 cells by western blotting. *P<0.05; **P<0.02 vs. without tetrazole.
(P<0.05) rise in apoptotic cell count in A549 and NCI-H1819 cells was observed on treatment with tetrazole. Exposure to 3-MA could not increase A549 and NCI-H1819 cell apoptotic percentage when compared to the control cells. Treatment with a combination of tetrazole (12 μM) and 3-MA led to a significant (P<0.02) elevation in A549 and NCI-H1819 cell apoptotic count relative to tetrazole alone treated cells. These finding indicated that tetrazole inhibited A549 and NCI-H1819 cell growth via autophagy activation. In A549 and NCI-H1819 cells tetrazole treatment promoted caspase-3 cleavage markedly at 12 μM doses relative to control cells. Exposure to 3-MA could not increase caspase-3 cleavage in A549 and NCI-H1819 cells. However, when A549 and NCI-H1819 cells were treated with tetrazole and 3-MA combination, cleaved caspase-3 level showed marked up-regulation relative to tetrazole-treated cells.

CONCLUSION

In summary, tetrazole manifested anti-proliferative effect on lung cancer cells via autophagy over-activation and the arrest of cell cycle. It deactivated ERK1/2 signalling and promoted mTOR signaling in A549 and NCI-H1819 cells to regulate cancer proliferation. Thus, tetrazole needs to be studied further as an anti-proliferaive agent for the treatment of lung cancer.

Acknowledgements

Not applicable.

Competing interests

The authors declare that there is no conflict of interest to disclose.

Statement of Ethics

The approval for present study was obtained from the Research Ethics Committee, The Third People’s Hospital of Chengdu, Sichuan, China. All the experimental procedures were conducted in accordance with the guidelines issued by National Institute of Health (NIH, USA).

SUMMARY

Treatment with 12 μM tetrazole suppressed viabilities to 23% and 20% in A549 and NCI-H1819 cells, respectively. In tetrazole exposed cells, G1-phase cell count increased significantly compared to the control. Tetrazole-treatment of A549 and NCI-H1819 cells caused a prominent rise in LC3-II and p-ERK1/2 expression. The SQSTM1/p62 level, p-mTOR and p-p70S6K expression was significantly lowered in A549 and NCI-H1819 cells on exposure to tetrazole. Exposure to U1026 alleviated tetrazole mediated LC3II/I ratio increase in A549 and NCI-H1819 cells significantly (P<0.02) compared to tetrazole treated cells. Treatment with tetrazole and 3-MA in combination led a significant (P<0.02) elevation in A549 and NCI-H1819 cell apoptotic count relative to tetrazole (12 μM) alone treated cells. Tetrazole and 3-MA combination increased cleavage of caspase-3 to a greater extent compared to tetrazole.

Authors’ contributions

Hongyan Zhang conceived and designed the study, Liangjiang Zhang, Jun Zhang, Jia Fan, Yuxin He, Tingting Zhan performed experimental work and carried our literature survey. Liwen Rong, Liangjiang Zheng and Jun Zhang compiled and analysed the data. Hongyang Zhang and Liangjiang Zheng wrote the paper. All the authors approved the paper for publication.

REFERENCES

Bachar SC, Lahini SC (2004) Synthesis of chloro and bromo substituted 5-(indan-1′-yl) tetrazoles and 5-(indan-1′-yl)methyltetrazoles as possible analgesic agents. Pharmazie 59: 435. https://doi.org/10.1022/0022-2755:200459118
Belkht AA, El-Sayed OA, Aboulmagd E, Park JY (2004) Tetrazolol,5'-quinoline as a potential promising new scaffold for the synthesis of novel anti-inflammatory and antibacterial agents. Eur J Med Chem 39: 249–255. https://doi.org/10.1016/j.ejmech.2003.12.005
Bolt AM, Zhao F, Pacheco S, Klimecki WT (2012) Arsenite-induced autophagy is associated with proteotoxicity in human lymphoblastoid cells. Toxicol Appl Pharmacol 264: 255–261. https://doi.org/10.1016/j.taap.2012.08.006
Bursch W (2001) The autophagosomal-lysosomal compartment in programmed cell death. Cell Death Differ 8: 569–581. https://doi.org/10.1038/sj.jcd.11010852
Cayatte S, Chambard JC (2010) ERK and cell death: Mechanisms of ERK-induced cell death-apoptosis, autophagy and senescence. FEBS J 277: 2–21. https://doi.org/10.1111/j.1742-4658.2009.07366.x
Dancey JE, Bedard PL, Onetto N, Hudson TJ (2012) The genetic basis for cancer treatment drug resistance. Cell 149: 419–420. https://doi.org/10.1016/j.cell.2012.01.014
Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, Copeland RA, Magonla RL, Secherle PA, Trzaskos JM (1998) Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273: 18623–18632. https://doi.org/10.1074/jbc.273.29.18623
Fukazawa H, Noguchi K, Murakami Y, Uchara Y (2002) Mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitors restore anokis sensitivity in human breast cancer cell lines with a constitutively activated extracellular-regulated kinase (ERK) pathway. Mol Cancer Ther 1: 303–309. PMID: 12489640
Hallinan EA, Tsybalov S, Dorn CR, Pirzade BS, Jr., Hansen DW (2002) Synthesis and biological characterization of L-N6-(1-iminoethyl)lysine 5-tetrazole-amide, a produrg of a selective iNOS inhibitor. J Med Chem 45: 1686–1689. https://doi.org/10.1021/jm010420e
Holokawa N, Hara T, Iizuka T, Kishi C, Takamura A, Murata Y, Inamura S, Natsume T, Takechana K, Yamada N, Guan JL, Oshiro N, Mizushima N (2009) Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy. Mol Biol Cell 20: 1981–1991. https://doi.org/10.1091/mbc.e08-12-1248
Kharas MG, Okabe R, Ganis JJ, Gozo M, Khandan T, P akinvat M, Gilliland DG, Gritsans K (2010) Constitutively active Akt depletes hematopoietic stem cells and induces leukemia in mice. Blood 115: 616–625. https://doi.org/10.1182/blood-2009-06-224533
Kliosnky DJ, Abdalla FC, Abielovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA et al. (2012) Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 8: 485–544. https://doi.org/10.4161/auto.19496
Kliosnky DJ (2014) Coming soon to a journal near you—the updated guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 10: 1691. https://doi.org/10.4161/auto.36187
Meepagala KM, Schrader KK, Wedge DE, Duke SO (2005) Algicidal and antifungal compounds from the roots of Ruta graveolens and comparison of assays for monitoring autophagy. Der PharmaChemica 14: 837–848. https://doi.org/10.1016/j.dphc.2005.05.005
Mihaylova MM, Shaw RJ (2011) The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol 13: 277–288. https://doi.org/10.1038/ncb2339
Natrajan U, Kallippa I, Singh NK (2010) A facile design and efficient synthesis of schiff’s bases of tetrazolo[1,5-a]quinolines as potential anti-inflammatory and anti-microbial agents. Der PharmaChemia 21: 159–167. https://derpharmachemica.com/vol2-is1
Nazio F, Strappazon F, Antonioli M, Bielli P, Cianfanelli V, Bordi M, Gretzemeier C, Dengiel J, Placentini M, Fimia GM, Cecconi F (2013) mTOR inhibits autophagy by controlling ULK1 ubiquitylation, self-association and function through AMBRA1 and TRAF6. Autophagy 9: 1981–1991. https://doi.org/10.4161/auto.19496
Popova Elena EA, Protas V, TrinoforovRostislav RE (2017) Tetrazole Derivatives as Promising-Anticancer Agent. Anti-cancer agents in Med Chem 17: 990–1017. https://doi.org/10.2174/15701667173217143148
Pathak S, Multani AS, Baneri P, Baneri P (2003) Ruta 6 selectively induces cell death in brain cancer cells but proliferation in normal peripheral blood lymphocytes: A novel treatment for human brain cancer. Int J Oncol 23: 975–982. PMID: 12693976
Pyo JO, Nah J, Jung YK (2012) Molecules and their functions in autophagy. *Exp Mol Med* 44: 73–80. https://doi.org/10.3858/emm.2012.44.2.029

Schmidt-Kittler O, Zha J, Yang J, Liu G, Hendricks W, Lengauer C, Gabelli SB, Kinzler KW, Vogelstein B, Huso DL, Zhou S (2010) PI3Kα inhibitors that inhibit metastasis. *Oncotarget* 1: 339–348. https://doi.org/10.18632/oncotarget.166

Sharma A, O’Connor R, Celestino P, Kilkion S, Griswold-Krupski L, Bansal-Travers M (2019) Focus groups and in-depth interviews to guide the development of lung cancer screening informational materials. *J Cancer Educ* 34: 712–718. https://doi.org/10.1007/s13187-018-1362-4

Santoni M, Amantini C, Morelli MB, Liberati S, Farfariello V, Nabissi M, Bonìli I, Eleuteri AM, Mozzicafreddo M, Bucatti I, Berardi R, Cuscinì S, Santoni G (2013) Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells. *Br J Cancer* 109: 1040–1050. https://doi.org/10.1038/bjc.2013.420

Shimizu S, Kanaseki T, Mizushima N, Mizuta T, Arakawa-Kobayashi S, Thompson CB, Tsujimoto Y (2004) Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. *Nat Cell Biol* 6: 1221–1228. https://doi.org/10.1038/ncb1192

Seymore L (1999) ovel anti-cancer agents in development: exciting prospects and new challenges. *Cancer Treat Rev* 25: 501–12. https://doi.org/10.1016/s0305-7372(99)00013-4

Tang Z, Li J, Shen Q, Feng J, Liu H, Wang W, Xu L, Shi G, Ye X, Ge M, et al. (2017) Contribution of upregulated dipeptidyl peptidase 9 (DPP9) in promoting tumorigenesis, metastasis and the prediction of poor prognosis in non-small cell lung cancer (NSCLC). *Int J Cancer* 140: 1620–1632. https://doi.org/10.1002/jjc.30571

Tanida I (2011) Autophagosome formation and molecular mechanism of autophagy. *Antioxid Redox Signal* 14: 2201–2214. https://doi.org/10.1089/ars.2010.3482

Wang SH, Shih YL, Ko WC, Wei YH, Shih CM (2008) Cadmium-induced autophagy and apoptosis are mediated by a calcium signaling pathway. *Cell Mol Life Sci* 65: 3640–3652. https://doi.org/10.1007/s00018-008-8383-9

Yang R-Y, Ali SM, Ashwell MA, Kelleher E, Palma R, Westlund N (2009) US Patent, 2009; 0130117A1